π¬Deep Research
URGN β UroGen Pharma Ltd Β· catalysts, narrative & risks
UroGen Pharma Ltd. (NASDAQ: URGN) β Research Snapshot as of 2026-10-03
Brief Profile
URGN trades on the NASDAQ and is positioned as a commercial-stage uro-oncology/biotechnology company with two marketed products β ZUSDURI (Zusduri) and Jelmyto β plus an advancing pipeline [1][8]. The stock closed at roughly $41.40 on October 2, 2026, with a market capitalization near $2.0B [11][13].
Recent Catalysts (roughly JulyβOctober 2026)
AI-assisted research from the K3vl4r desk β not personalized investment advice. More research β